Despite mixed results from Trauma players, the segment experienced healthy growth as mergers and acquisitions were plentiful and regulatory clearances show promise of future new product introductions.
Despite an overall healthy first quarter for the Trauma Market, players in the space reported mixed results. Top players DePuy Synthes* and Stryker experienced healthy returns while Smith & Nephew* and Zimmer Biomet* noted headwinds based on geography and product category. Globus, no longer a real newcomer to the trauma segment, but a company SmartTRAK continues to monitor, experienced its strongest quarter to date and the Company continues to expand its salesforce.
Among the many topics covered in detail in our comprehensive Q122 Trauma Market Recap* are:
- Complete Q122 Trauma Market Overview
- SmartTRAK's Expert Analysis and Insights
- All Market News including Revenues, Data, Charts and Shares
- Mixed Results for Trauma Players
- Mergers & Acquisitions Impact Trauma & Extremities
- Regulatory Highlights Indicate New Future Product Offerings
Deals in the Extremities space outpaced 2021 with three acquisitions completed in the first quarter of 2022 and a strategic partnership announced. In January, Paragon 28 acquired ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. 
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.
